SPACs increasingly are being used to take private biotech and health-care companies public, but they raise special due diligence issues because the companies are highly regulated and their products affect patients, Bloomberg reports, citing Reed Smith attorneys. They outline several key aspects that need extra scrutiny.
Due diligence for biotechnology companies is critical because they tend to be highly regulated by multiple government agencies, and the products can directly affect patients’ health and well-being. Without proper due diligence, latent problems could cause issues at any moment, putting the company and its investors’ funds at risk. Read more.
Related Posts
VG Shares and Warrants Begin Separate Trading
VG Acquisition announced that stockholders may separately trade shares and warrants starting today.
Big Law Is Bullish on SPACs Even as Large Banks Pull Out
Lawyers are advising SPACs, investors, and target companies on what the rules will mean for deals being negotiated now and those that could occur down the line.
London SPAC Ditches Effort to Raise Funds for Insurance Deal
Financials Acquisition terminated a plan to invest £150 million or more in insurance market Lloyd’s of London.
SilverBox’s Latest SPAC Fundraise Makes the Case for Thinking Small
For SilverBox Capital Managing Partner Joe Reece, the shrunken SPAC is more investor- and target-friendly. It pays lower fees to bankers, has less of an overhang from sweeteners like warrants that can dilute ownership and gives sponsors a smaller share of the merged company.